October 20, 2008

Type I Interferon in the Induction or Exacerbation of DermatomyositisWhat This Observation Tells Us About the Naturally Occurring Disease

Author Affiliations

Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008

Arch Dermatol. 2008;144(10):1379-1382. doi:10.1001/archderm.144.10.1379

Adverse events associated with medication use are a bane for physicians. However, when an adverse effect goes beyond an isolated clinical or laboratory finding and is instead a phenocopy of a naturally occurring disease state, we are presented with an opportunity to understand disease pathogenesis. The less common situation in which a disease state is reproduced with a naturally occurring biologic substance (ie, cytokine or hormone) makes even the most jaded of clinicians stand up and take note. The association of supraphysiologic amounts of an endogenous molecule with an induced disease state hardly provides physiologic proof of its connection in the spontaneously occurring disease, but it provides another level of evidence in a world in which the study of human disease rarely affords one with the opportunity to perform an in vivo experiment. It is with this level of interest and caution that we should approach the article in this issue of the Archives by Somani et al,1 in which the administration of interferon beta is associated with new-onset dermatomyositis.

First Page Preview View Large
First page PDF preview
First page PDF preview